

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 23:03:23 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: BioCentury coverage of mAbs to treat COVID-19

Please handle.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Karen Tkach Tuzman <ktkach@biocentury.com>  
**Sent:** Wednesday, February 19, 2020 5:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** BioCentury coverage of mAbs to treat COVID-19  
**Importance:** High

Dear Dr. Fauci,

I hope all is well. BioCentury is doing a roundup of companies and institutions developing antibodies against the SARS-CoV-2 virus to treat patients with COVID-19. Since you told my colleague Steve Usdin NIAID is developing its own mAbs against the virus, we'd like to include information about that program in our roundup.

Would you or one of your colleagues be able to answer the following questions? Any information you could share by 5 PM Pacific Time on Thursday, Feb. 20 would be greatly appreciated.

1. Are your mAb candidates being developed against specific targets on SARS-CoV-2? If so, what are those targets?
2. What platforms or processes are you using to identify mAb candidates?
3. Do you have multiple mAb programs against SARS-CoV-2 proceeding in parallel, and if so, how are they distinguished?